WO2003019457A3 - Methode destinee a optimiser le remplacement de l'hormone de croissance - Google Patents

Methode destinee a optimiser le remplacement de l'hormone de croissance Download PDF

Info

Publication number
WO2003019457A3
WO2003019457A3 PCT/US2002/027175 US0227175W WO03019457A3 WO 2003019457 A3 WO2003019457 A3 WO 2003019457A3 US 0227175 W US0227175 W US 0227175W WO 03019457 A3 WO03019457 A3 WO 03019457A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth hormone
dose
hormone replacement
hgh
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/027175
Other languages
English (en)
Other versions
WO2003019457A2 (fr
Inventor
Michael B Foster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renasci Inc Dba Renasci Anti-Aging Center
RENASCI Inc dba RENASCI ANTI
Original Assignee
Renasci Inc Dba Renasci Anti-Aging Center
RENASCI Inc dba RENASCI ANTI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renasci Inc Dba Renasci Anti-Aging Center, RENASCI Inc dba RENASCI ANTI filed Critical Renasci Inc Dba Renasci Anti-Aging Center
Publication of WO2003019457A2 publication Critical patent/WO2003019457A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003019457A3 publication Critical patent/WO2003019457A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Primary Health Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode destinée à reconstituer l'hormone de croissance humaine (HCH) chez un humain adulte. Cette méthode consiste à administrer quotidiennement une dose initiale de HCH pendant trois à quatre semaines, puis à déterminer une dose d'entretien individualisée par détermination de la réaction de l'individu à des doses progressivement accrues de HCH. On administre alors cette dose d'entretien, habituellement dans une préparation de microsphères, d'où une réduction de la fréquence de dosage. Cette méthode est utile pour atténuer certains effets du vieillissement chez les adultes.
PCT/US2002/027175 2001-08-27 2002-08-26 Methode destinee a optimiser le remplacement de l'hormone de croissance Ceased WO2003019457A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/939,962 US20020155990A1 (en) 2001-04-20 2001-08-27 Method of optimizing growth hormone replacement
US09/939,962 2001-08-27

Publications (2)

Publication Number Publication Date
WO2003019457A2 WO2003019457A2 (fr) 2003-03-06
WO2003019457A3 true WO2003019457A3 (fr) 2004-04-08

Family

ID=25474006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/027175 Ceased WO2003019457A2 (fr) 2001-08-27 2002-08-26 Methode destinee a optimiser le remplacement de l'hormone de croissance

Country Status (2)

Country Link
US (1) US20020155990A1 (fr)
WO (1) WO2003019457A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US20100022487A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
AR093908A1 (es) * 2012-12-12 2015-06-24 Teva Pharma Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma
CA3214273A1 (fr) * 2021-03-19 2022-09-22 Opko Biologics Ltd. Procedes d'administration de polypeptides d'hormone de croissance a action prolongee

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883370A (en) * 1995-06-08 1999-03-16 Psc Inc. Automated method for filling drug prescriptions
US6101478A (en) * 1997-04-30 2000-08-08 Health Hero Network Multi-user remote health monitoring system
WO2001022343A2 (fr) * 1999-09-21 2001-03-29 Cardiocom Systeme de gestion de l'etat de sante, appareil et methode
WO2001050950A2 (fr) * 2000-01-11 2001-07-19 Zycare, Inc. Appareil et methodes permettant de surveiller une therapie d'anticoagulation et de la modifier chez des patients eloignes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883370A (en) * 1995-06-08 1999-03-16 Psc Inc. Automated method for filling drug prescriptions
US6101478A (en) * 1997-04-30 2000-08-08 Health Hero Network Multi-user remote health monitoring system
WO2001022343A2 (fr) * 1999-09-21 2001-03-29 Cardiocom Systeme de gestion de l'etat de sante, appareil et methode
WO2001050950A2 (fr) * 2000-01-11 2001-07-19 Zycare, Inc. Appareil et methodes permettant de surveiller une therapie d'anticoagulation et de la modifier chez des patients eloignes

Also Published As

Publication number Publication date
WO2003019457A2 (fr) 2003-03-06
US20020155990A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
Bjurholm et al. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR‐106–01, ROS 17/2.8, MC3T3‐E1, and Saos‐2) and primary bone cells
Wronski et al. Skeletal alterations in ovariectomized rats
EP1294384B1 (fr) Traitement des maladies osseuses avec le lanthane
WO2003019457A3 (fr) Methode destinee a optimiser le remplacement de l'hormone de croissance
PL339290A1 (en) Pharmacological preparation containing clodronate as its active ingredient and silicated monocrystalline cellulose as excipient
AU2252592A (en) Method of stimulating immune response
AU6522090A (en) Bicyclic pyrimidine derivative, method of producing the same, and pharmaceutical preparation containing the same as active ingredient
WO2002015720A3 (fr) Composition et procede nutritionnels permettant d'ameliorer le depot proteique
DE60027575D1 (de) Verwendung von Spinosad oder einer Zusammensetzung enthaltend spinosad
CA2101275A1 (fr) Methodes de traitement de l'osteoporose
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
WO1999018911A3 (fr) Compositions de porcelaine usinables renfermant de la leucite et leurs procedes de fabrication
AU4746700A (en) Compound preparation made of vitamin d metabolites or vitamin d analogues and anoestrogenic component for treating osteoporosis
NO20033967L (no) Fremgangsmåte for fremstilling av mikropartikler som inneholder metoprolol
Furuta et al. Effect of 16, 16‐dimethyl prostaglandin E2 methyl ester on weanling rat skeleton: daily and systemic administration
NZ506095A (en) Cosmetic composition containing a compound with stimulatory activity on interleukin-6 (IL-6) production by keratinocytes
Baume et al. Response of condylar growth cartilage to induced stresses
Modeer et al. Enhanced prostaglandin biosynthesis in human gingival fibroblasts isolated from patients treated with phenytoin
Clayden et al. Ultrastructure of cementogenesis as affected by growth hormone in the molar periodontium of the hypophysectomized rat
HUT58282A (en) Process for producing new, cyclic ketone derivatives and pharmaceutical compositions containing them as active components
NO950950L (no) Farmasöytisk preparat
Craig et al. The effect of endodontic materials on periodontal ligament cell proliferation, alkaline phosphatase activity, and extracellular matrix protein synthesis in vitro
AR007480A1 (es) Metodo para producir masa fermentada para pan, uso de un compuesto generador de acido, y de la masa para pan, producto horneado y composicion debase de masa para pan
LEPPERT et al. In vivo effect of human growth hormone on hepatic adenylate cyclase activity
Takizawa et al. The effect of a new vitamin D analog, 22-oxa-1α, 25 (OH) 2D3, on bone mineral metabolism in normal male rats

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: COMMUNICATION UNDER RULE 69 EPC (EPO FORM 1205A DATED 30.07.2004)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP